$30.19 Million in Sales Expected for NanoString Technologies, Inc. (NSTG) This Quarter
Wall Street analysts expect NanoString Technologies, Inc. (NASDAQ:NSTG) to post sales of $30.19 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for NanoString Technologies’ earnings, with estimates ranging from $28.90 million to $31.38 million. NanoString Technologies reported sales of $25.23 million in the same quarter last year, which suggests a positive year over year growth rate of 19.7%. The business is expected to issue its next quarterly earnings results on Wednesday, March 7th.
According to Zacks, analysts expect that NanoString Technologies will report full year sales of $30.19 million for the current financial year, with estimates ranging from $109.96 million to $111.74 million. For the next year, analysts forecast that the business will post sales of $112.39 million per share, with estimates ranging from $105.00 million to $123.41 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for NanoString Technologies.
NanoString Technologies (NASDAQ:NSTG) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.11. NanoString Technologies had a negative net margin of 44.24% and a negative return on equity of 174.55%. The firm had revenue of $27.02 million during the quarter, compared to analysts’ expectations of $26.27 million. During the same period last year, the business earned ($0.51) earnings per share. NanoString Technologies’s revenue was up 12.9% compared to the same quarter last year.
Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of NanoString Technologies during the third quarter valued at about $124,000. Bank of Montreal Can boosted its stake in shares of NanoString Technologies by 3,731.4% in the second quarter. Bank of Montreal Can now owns 9,387 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 9,142 shares during the period. Trexquant Investment LP purchased a new position in shares of NanoString Technologies in the third quarter valued at approximately $203,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of NanoString Technologies in the third quarter valued at approximately $222,000. Finally, Bank of America Corp DE boosted its stake in shares of NanoString Technologies by 16.6% in the first quarter. Bank of America Corp DE now owns 11,404 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 1,627 shares during the period. Institutional investors and hedge funds own 92.72% of the company’s stock.
NanoString Technologies (NSTG) traded down $0.06 during trading on Friday, reaching $7.40. 232,700 shares of the company traded hands, compared to its average volume of 205,635. NanoString Technologies has a 52-week low of $7.03 and a 52-week high of $23.31. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 1.08.
TRADEMARK VIOLATION WARNING: “$30.19 Million in Sales Expected for NanoString Technologies, Inc. (NSTG) This Quarter” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/08/30-19-million-in-sales-expected-for-nanostring-technologies-inc-nstg-this-quarter.html.
NanoString Technologies Company Profile
NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.